Harvard Biosci Stock Price, News & Analysis

Harvard Bioscience (NASDAQ: HBIO) will report financial results for the quarter ended September 30, 2025 before market open on November 6, 2025. The company will host a conference call to discuss results at 8:00 AM Eastern Time on the same day.

Participants who wish to ask questions must register to receive dial-in numbers and a unique PIN. An audio-only webcast will be available via the company’s Investor Relations events and presentations page. The earnings release and related slide presentation will be posted in the Investor Relations section.

Harvard Bioscience (Nasdaq: HBIO) has expanded its distribution agreement with Fisher Scientific to include the United States market, building upon their existing European partnership. The expanded agreement enables Fisher Scientific to distribute Harvard Bioscience's pumps, spectrophotometers, and BTX electroporation systems throughout the U.S.

The strategic expansion gives Harvard Bioscience access to hundreds of Fisher Scientific sales representatives and their extensive U.S. distribution network. The partnership will offer both established product lines and emerging technologies, including the Mesh MEA for advanced organoid research. This collaboration aims to enhance customer experience through streamlined ordering, faster delivery, and localized support.

Harvard Bioscience (Nasdaq: HBIO) has announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. DeNelsky, who brings 30 years of healthcare industry experience, will serve on the Board's Nominating and Governance Committee.

Currently serving as Managing Director at Oaktree Capital Management, DeNelsky has extensive experience in research, analysis, and valuation of healthcare equities. He also serves on the board of Visioncare Inc and previously held board positions at Integrated Diagnostics and AMICAS, Inc. His expertise spans life sciences, pharmaceuticals, devices, and services sectors.

Harvard Bioscience (NASDAQ:HBIO) reported Q2 2025 financial results with revenues of $20.5 million, exceeding guidance but down from $23.1 million in Q2 2024. The company achieved a gross margin of 56.4% and positive cash flow from operations of $2.8 million.

Key developments include a credit agreement amendment extending the refinancing deadline to December 5, 2025, with lenders waiving previous defaults. The company reported a net loss of ($2.3) million, improving from ($2.9) million in Q2 2024, while Adjusted EBITDA increased to $1.5 million from $1.3 million.

For Q3 2025, HBIO projects revenues between $19-21 million with gross margins of 56-58%. The company's priorities focus on core business growth and balance sheet restructuring, aiming for revenue growth and margin expansion in 2026.

[ "Positive cash flow from operations of $2.8M in Q2 2025, compared to -$0.8M in Q2 2024", "Credit agreement amendment secured, extending refinancing deadline to December 5, 2025", "Q2 2025 net loss improved to -$2.3M from -$2.9M year-over-year", "Adjusted EBITDA increased to $1.5M from $1.3M in Q2 2024" ]

Harvard Bioscience (Nasdaq: HBIO) has scheduled its second quarter 2025 earnings conference call for August 11, 2025, at 8:00 AM ET. The company will release its financial results for the quarter ended June 30, 2025, before the market opens on the same day.

Interested participants who wish to ask questions during the call must pre-register to receive dial-in numbers and a unique PIN. An audio-only webcast option is also available through the company's investor website. The earnings release and related presentation materials will be accessible through Harvard Bioscience's Investor Relations section.

Harvard Bioscience (NASDAQ: HBIO) announced a significant leadership transition as John Duke will succeed Jim Green as President & CEO effective July 28, 2025. Duke, a current board member and CEO of Plastic Molding Technology, brings extensive experience including a 20-year tenure at Corning Incorporated.

The company also appointed two new independent directors: Rob Gagnon, a former HBIO CFO (2013-2018) with over 20 years of life sciences experience, and Seth Benson, current CFO of Nuclera Ltd with significant life science tools expertise.

Additionally, Harvard Bioscience provided Q2 2025 guidance, expecting revenue of $20.4 million and reiterating gross margin guidance of 55% to 57%. Full Q2 2025 financial results will be reported on August 11, 2025.

Harvard Bioscience (NASDAQ: HBIO) has appointed John Duke to its Board of Directors effective June 2, 2025. Duke, 54, currently CEO of Plastic Molding Technology, brings extensive experience in life science tools and business execution. He previously served as EVP and Chief Business Officer at Lyten, Inc. and spent over 20 years at Corning Incorporated, including eight years leading their Life Sciences division. Duke holds a BS in Materials Science & Engineering from the University of Utah and an MBA from Harvard University. Additionally, Katherine Eade has been named Lead Independent Director, while Thomas Loewald, who served since October 2017, has retired from the board. Duke will serve on both the audit and nominating and governance committees.

Harvard Bioscience (NASDAQ: HBIO) reported its Q1 2025 financial results with revenues of $21.8 million, down from $24.5 million in Q1 2024. The company posted a net loss of $50.3 million, largely due to a $48.0 million goodwill impairment. Gross margin declined to 56.0% from 60.3% year-over-year. Despite challenges, cash from operations improved to $3.0 million from $1.4 million in Q1 2024. The company highlighted positive adoption of their MeshMEA™ organoid systems and new SoHo™ telemetry systems. Management announced cost reduction initiatives expected to save approximately $1 million per quarter starting Q2. For Q2 2025, HBIO forecasts revenues between $18-20 million with gross margins of 55-57%.

Harvard Bioscience (NASDAQ: HBIO) has announced it will release its financial results for Q1 2025 (quarter ended March 31, 2025) before market opens on May 12, 2025. The company will host a conference call at 8:00 AM Eastern Time to discuss the results. Interested participants who wish to ask questions must pre-register to receive dial-in numbers and a unique PIN. An audio-only webcast option is also available through the company's investor website. The earnings release and related presentation materials will be accessible through Harvard Bioscience's Investor Relations section.